These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26815784)

  • 41. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Co-occurrence of heterozygous mutations in
    Ji Y; Ikram A; Ma Z; Peppelenbosch MP; Pan Q
    J Genet; 2019 Jun; 98(2):. PubMed ID: 31204718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type V osteogenesis imperfecta: a new form of brittle bone disease.
    Glorieux FH; Rauch F; Plotkin H; Ward L; Travers R; Roughley P; Lalic L; Glorieux DF; Fassier F; Bishop NJ
    J Bone Miner Res; 2000 Sep; 15(9):1650-8. PubMed ID: 10976985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings.
    Li G; Jin Y; Levine MAH; Hoyer-Kuhn H; Ward L; Adachi JD
    Acta Paediatr; 2018 Mar; 107(3):534-537. PubMed ID: 29154388
    [No Abstract]   [Full Text] [Related]  

  • 47. Rare Association Between Osteogenesis Imperfecta and Chondrosarcoma: Could a Pathogenic Variant in the Gene SERPINF1 Explain It?
    Amorim DMR; Koga GKC; Dos Santos RN; Secundo PFC; de Ávila Fernandes E; Cardili L; Maeda SS; da Rocha Corrêa Fernandes A; Lazaretti-Castro M
    Calcif Tissue Int; 2023 Jan; 112(1):118-122. PubMed ID: 36322168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel Deletion of SERPINF1 Causes Autosomal Recessive Osteogenesis Imperfecta Type VI in Two Brazilian Families.
    Minillo RM; Sobreira N; de Faria Soares Mde F; Jurgens J; Ling H; Hetrick KN; Doheny KF; Valle D; Brunoni D; Perez AB
    Mol Syndromol; 2014 Dec; 5(6):268-75. PubMed ID: 25565926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab.
    Hoyer-Kuhn H; Stark C; Franklin J; Schoenau E; Semler O
    Pediatr Endocrinol Rev; 2017 Nov; 15(Suppl 1):123-129. PubMed ID: 29292876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new culprit in osteogenesis imperfecta.
    Germain-Lee EL
    J Bone Miner Res; 2011 Dec; 26(12):2795-7. PubMed ID: 22105742
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel mutation in a family with WNT1-related osteoporosis.
    Panigrahi I; Didel S; Kirpal H; Bellampalli R; Miyanath S; Mullapudi N; Rao S
    Eur J Med Genet; 2018 Jul; 61(7):369-371. PubMed ID: 29481978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case Report: A Novel Homozygous Variant of the
    Zhalsanova IZ; Postrigan AE; Valiakhmetov NR; Kolesnikov NA; Zhigalina DI; Zarubin AA; Petrova VV; Minaycheva LI; Seitova GN; Skryabin NA; Stepanov VA
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.
    Aström E; Magnusson P; Eksborg S; Söderhäll S
    Acta Paediatr; 2010 Dec; 99(12):1834-40. PubMed ID: 20726960
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New trends in the treatment of osteogenesis imperfecta type III - own experience.
    Jakubowska-Pietkiewicz E; Chlebna-Sokół D
    Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bisphosphonate treatment of children and adults with osteogenesis imperfecta: unanswered questions.
    Brizola E; Shapiro JR
    Calcif Tissue Int; 2015 Aug; 97(2):101-3. PubMed ID: 26071113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bone density measurements by computed tomography in osteogenesis imperfecta type I.
    Miller ME; Hangartner TN
    Osteoporos Int; 1999; 9(5):427-32. PubMed ID: 10550462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.